Medications
Perrigo to go it alone; shareholders reject $26B Mylan bid (Update)
Shareholders of the drugmaker Perrigo shut the door on a $26-billion hostile takeover bid from Mylan.
Nov 13, 2015
0
3
News tagged with bid
Other
Depomed rejects Horizon's latest takeover offer
Depomed Inc. on Monday rejected Horizon Pharma PLC's sweetened $2.4 billion hostile takeover offer, saying it still undervalues the company, and recommended that its shareholders reject the bid.
Sep 14, 2015
0
7
Other
Horizon takes hostile Depomed bid directly to shareholders
Horizon Pharma is pushing ahead with its hostile, $2.4-billion bid to buy Depomed by starting an offer to exchange a portion of its stock for shares of the rival drugmaker.
Sep 8, 2015
0
4
Medications
Big pharma deals: Mylan raises bid for Perrigo to $35.6 bn
Generic drug company Mylan raised its bid for a second time for Perrigo on Wednesday, offering $35.6 billion for the over-the-counter giant.
Apr 29, 2015
0
1
Medications
Teva offers to buy Mylan in $40.1B cash-and-stock deal
Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny ...
Apr 21, 2015
0
1
Other
Actavis to spend $66 billion on Allergan
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
Nov 17, 2014
0
0
Other
AstraZeneca profits tumble in third quarter
British pharmaceuticals group AstraZeneca announced on Thursday a slump in quarterly profits, in part on higher investment costs, but raised its outlook for full-year revenues.
Nov 6, 2014
0
0
Other
Valeant: We'll bump Allergan offer to $200 a share
The Canadian drugmaker Valeant said it would be willing to raise its takeover bid for Allergan by almost 12 percent, which would mean $200 or more per share for the maker of Botox.
Oct 27, 2014
0
0
Other
AbbVie to pay Shire $1.64B fee over nixed merger
AbbVie is walking away from its proposed $55 billion takeover bid of Shire and has agreed to pay the rival drugmaker a $1.64 billion breakup fee.
Oct 20, 2014
0
0
Other
Allergan tells shareholders to reject Valeant deal
Allergan, the maker of Botox, said Monday that Valeant Pharmaceuticals' hostile takeover bid for the company is "grossly inadequate" and that shareholders should reject it.
Jun 23, 2014
0
0
